MX2019006938A - Metodos y composiciones para trataminto de hipertension pulmonar y otros trastornos del pulmon. - Google Patents

Metodos y composiciones para trataminto de hipertension pulmonar y otros trastornos del pulmon.

Info

Publication number
MX2019006938A
MX2019006938A MX2019006938A MX2019006938A MX2019006938A MX 2019006938 A MX2019006938 A MX 2019006938A MX 2019006938 A MX2019006938 A MX 2019006938A MX 2019006938 A MX2019006938 A MX 2019006938A MX 2019006938 A MX2019006938 A MX 2019006938A
Authority
MX
Mexico
Prior art keywords
methods
pulmonary hypertension
compositions
treatment
vasodilator
Prior art date
Application number
MX2019006938A
Other languages
English (en)
Inventor
Donovan Martin
Weers Jeffrey
Smyth Hugh
Curtis Robert
frost Adaani
Shreeniwas Revati
Romero Alain
Xu Zhen
Original Assignee
Respira Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Respira Therapeutics Inc filed Critical Respira Therapeutics Inc
Publication of MX2019006938A publication Critical patent/MX2019006938A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se proporcionan en la presente métodos para tratar hipertensión pulmonar. Los métodos incluyen administrar a un sujeto en necesidad del mismo una cantidad efectiva de un vasodilatador, en donde el vasodilatador se administra al sujeto por la vía de la inhalación pro re nata o como sea requerido utilizando un inhalador portátil. En algunas modalidades, el vasodilatador es un inhibidor PDE5. También se describen composiciones farmacéuticas para administración pro re nata de los vasodilatadores.
MX2019006938A 2016-12-14 2017-12-14 Metodos y composiciones para trataminto de hipertension pulmonar y otros trastornos del pulmon. MX2019006938A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662434185P 2016-12-14 2016-12-14
PCT/US2017/066519 WO2018112258A1 (en) 2016-12-14 2017-12-14 Methods and compositions for treatment of pulmonary hypertension and other lung disorders

Publications (1)

Publication Number Publication Date
MX2019006938A true MX2019006938A (es) 2019-09-06

Family

ID=60888760

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019006938A MX2019006938A (es) 2016-12-14 2017-12-14 Metodos y composiciones para trataminto de hipertension pulmonar y otros trastornos del pulmon.

Country Status (10)

Country Link
US (4) US10912778B2 (es)
EP (1) EP3554507A1 (es)
JP (2) JP2020502121A (es)
CN (1) CN110381951A (es)
AU (2) AU2017378409A1 (es)
BR (1) BR112019012251A2 (es)
CA (1) CA3046025A1 (es)
MX (1) MX2019006938A (es)
RU (1) RU2019121646A (es)
WO (1) WO2018112258A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2700989T3 (es) 2012-12-21 2019-02-20 Mayo Found Medical Education & Res Métodos y materiales para tratar estenosis de la válvula aórtica calcificada
US10898494B2 (en) 2016-05-05 2021-01-26 Liquidia Technologies, Inc. Dry powder treprostinil for the treatment of pulmonary hypertension
EP3554507A1 (en) 2016-12-14 2019-10-23 Respira Therapeutics, Inc. Methods and compositions for treatment of pulmonary hypertension and other lung disorders
US20180325908A1 (en) * 2017-01-10 2018-11-15 United Therapeutics Corporation Methods and compositions for treating pulmonary hypertension
WO2020210707A1 (en) * 2019-04-10 2020-10-15 Mayo Foundation For Medical Education And Research Methods and materials for gender-dependent treatment of cardiovascular dysfunction
EP3979990A1 (en) * 2019-06-10 2022-04-13 Respira Therapeutics, Inc. Carrier-based formulations and related methods
CN112569210B (zh) * 2019-09-27 2023-09-15 盈科瑞（天津）创新医药研究有限公司 一种吸入用马昔腾坦溶液及其制备方法
CN112773898A (zh) * 2019-11-11 2021-05-11 广州华真医药科技有限公司 磷酸二酯酶5抑制剂在制备抗纤维化疾病药物中的应用
CN110946826B (zh) * 2019-12-12 2022-02-22 烟台大学 一种利奥西呱口服制剂及其制备方法
CN118201620A (zh) 2021-09-10 2024-06-14 尤斯图斯-李比希大学 吸入的伊洛前列素用于肺动脉高压的按需治疗
CN116687888A (zh) * 2023-06-02 2023-09-05 苏州易合医药有限公司 伐地那非和达泊西汀复方干粉吸入制剂及其制备方法

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1338235A (en) 1970-12-15 1973-11-21 May & Baker Ltd Azapurinones
GB1493685A (en) 1970-12-15 1977-11-30 May & Baker Ltd 8-azapurinones
US4883812A (en) 1976-08-17 1989-11-28 Burroughs Wellcome Co. Treatment of hypertension using prostacyclin
US4306075A (en) 1980-03-28 1981-12-15 The Upjohn Company Composition and process
JPS58124778A (ja) 1982-01-20 1983-07-25 Toray Ind Inc ５，６，７−トリノル−４，８−インタ−ｍ−フエニレンＰＧＩ↓２誘導体
DE3417638A1 (de) 1984-05-10 1985-11-14 Schering AG, 1000 Berlin und 4709 Bergkamen Verfahren zur bestimmung geringer stoffmengen von arzneimitteln, von koerpereigenen oder anderen chemischen substanzen in biologischem material
US5250534A (en) 1990-06-20 1993-10-05 Pfizer Inc. Pyrazolopyrimidinone antianginal agents
GB9401090D0 (en) 1994-01-21 1994-03-16 Glaxo Lab Sa Chemical compounds
GB9514464D0 (en) 1995-07-14 1995-09-13 Glaxo Lab Sa Medicaments
US6565885B1 (en) 1997-09-29 2003-05-20 Inhale Therapeutic Systems, Inc. Methods of spray drying pharmaceutical compositions
US6441245B1 (en) 1997-10-24 2002-08-27 United Therapeutics Corporation Process for stereoselective synthesis of prostacyclin derivatives
HU230154B1 (hu) 1997-11-12 2015-09-28 Bayer Intellectual Property Gmbh Eljárás 2-es helyzetben fenil-szubszituenst hordozó imidazo-triazinon-származékok előállítására
DE19834044A1 (de) 1998-07-29 2000-02-03 Bayer Ag Neue substituierte Pyrazolderivate
US6521212B1 (en) 1999-03-18 2003-02-18 United Therapeutics Corporation Method for treating peripheral vascular disease by administering benzindene prostaglandins by inhalation
US6943166B1 (en) 1999-04-30 2005-09-13 Lilly Icos Llc. Compositions comprising phosphodiesterase inhabitors for the treatment of sexual disfunction
US6821975B1 (en) 1999-08-03 2004-11-23 Lilly Icos Llc Beta-carboline drug products
AU4491200A (en) 1999-08-03 2001-02-19 Lilly Icos Llc Beta-carboline pharmaceutical compositions
CN1374953A (zh) 1999-09-16 2002-10-16 田边制药株式会社 含氮的6－员芳香环化合物
ATE552013T1 (de) 2000-09-06 2012-04-15 Mitsubishi Tanabe Pharma Corp Zubereitungen zur oralen anwendung
WO2002079143A1 (en) 2001-03-28 2002-10-10 Pfizer Limited N-phenpropylcyclopentyl-substituted glutaramide derivatives as nep inhibitors for fsad
TWI316055B (es) 2001-04-26 2009-10-21 Nippon Shinyaku Co Ltd
DE10220570A1 (de) 2002-05-08 2003-11-20 Bayer Ag Carbamat-substituierte Pyrazolopyridine
US20040077624A1 (en) 2002-05-23 2004-04-22 Pfizer Inc. Novel combination
CA2536293A1 (en) * 2003-08-22 2005-03-03 Boehringer Ingelheim Pharmaceuticals, Inc. Methods of treating copd and pulmonary hypertension
EP1898879A1 (en) 2005-06-23 2008-03-19 Schering Corporation Rapidly absorbing oral formulations of pde5 inhibitors
CA2641393C (en) 2006-02-03 2014-12-16 Scidose Llc Novel epoprostenol formulation and method of making thereof
WO2007134292A2 (en) 2006-05-15 2007-11-22 United Therapeutics Corporation Treprostinil administration using a metered dose inhaler
KR101898407B1 (ko) 2007-12-17 2018-09-12 유나이티드 세러퓨틱스 코오포레이션 레모둘린®의 활성 성분인 트레프로스티닐의 개선된 제조 방법
EP2237788A4 (en) 2007-12-27 2013-06-05 Aires Pharmaceuticals Inc COMPOUNDS FOR OBTAINING AEROSOLIZED NITRITE AND NITRIC OXIDE AND USES THEREOF
KR20240024285A (ko) 2008-03-18 2024-02-23 아레나 파마슈티칼스, 인크. 프로스타시클린 （ｐｇｉ２） 수용체와 관련된 장애의 치료에 유용한 상기 수용체의 조절제
WO2009115235A1 (en) 2008-03-20 2009-09-24 Bayer Schering Pharma Aktiengesellschaft Pde inhibitors for the treatment of pulmonary hypertension
NO2315587T3 (es) 2008-08-13 2018-03-24
US8791122B2 (en) 2009-06-26 2014-07-29 Nippon Shinyaku Co., Ltd. Form-I crystal of 2-{4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy}-N-(methylsulfonyl)acetamide and method for producing the same
WO2011030351A2 (en) 2009-09-03 2011-03-17 Rubicon Research Private Limited Taste - masked pharmaceutical compositions
EP2480526A1 (en) 2009-09-23 2012-08-01 Arena Pharmaceuticals, Inc. Crystalline forms and processes for the preparation of pgi2 receptor agonists
KR20130061148A (ko) 2010-05-03 2013-06-10 티에스에이치 바이오팜 코포레이션 리미티드 고혈압 치료용 약학 조성물 및 방법
EA022046B1 (ru) 2010-07-14 2015-10-30 Новартис Аг Гетероциклические соединения, агонисты рецептора ip
WO2012030647A1 (en) 2010-08-30 2012-03-08 Pulmatrix, Inc. Treatment of cystic fibrosis using calcium lactate, leucine and sodium chloride in a respiraple dry powder
WO2012078804A1 (en) 2010-12-07 2012-06-14 Respira Therapeutics, Inc. Dry powder inhaler
US10463815B2 (en) 2012-02-21 2019-11-05 Respira Therapeutics, Inc. Inhaler to deliver substances for prophylaxis or prevention of disease or injury caused by the inhalation of biological or chemical agents
US20160317542A1 (en) 2013-12-09 2016-11-03 Respira Therapeutics, Inc. Pde5 inhibitor powder formulations and methods relating thereto
CN106794325B (zh) 2014-02-21 2020-06-30 瑞必治公司 粉末吸入器、系统和方法
CA2973114C (en) * 2015-01-13 2023-04-04 Vivus, Inc. Combination therapy for pulmonary hypertension
EP3554507A1 (en) 2016-12-14 2019-10-23 Respira Therapeutics, Inc. Methods and compositions for treatment of pulmonary hypertension and other lung disorders

Also Published As

Publication number Publication date
AU2022256085A1 (en) 2022-11-17
EP3554507A1 (en) 2019-10-23
US11491160B2 (en) 2022-11-08
US20220347183A1 (en) 2022-11-03
US11491161B2 (en) 2022-11-08
US20220079949A1 (en) 2022-03-17
JP2020502121A (ja) 2020-01-23
US10912778B2 (en) 2021-02-09
CA3046025A1 (en) 2018-06-21
AU2017378409A1 (en) 2019-07-04
RU2019121646A3 (es) 2021-03-17
US20200093830A1 (en) 2020-03-26
US20210205318A1 (en) 2021-07-08
BR112019012251A2 (pt) 2019-11-05
RU2019121646A (ru) 2021-01-15
JP2023036678A (ja) 2023-03-14
WO2018112258A1 (en) 2018-06-21
CN110381951A (zh) 2019-10-25

Similar Documents

Publication Publication Date Title
MX2019006938A (es) Metodos y composiciones para trataminto de hipertension pulmonar y otros trastornos del pulmon.
ZA202103404B (en) Composition and method for treating the lungs
CY1120049T1 (el) (2s)-ν-[(1s)-1-κυανο-2-φαινυλαιθυλ]-1,4-οξαζεπαν-2-καρβοξαμιδια ως αναστολεις της διπεπτιδυλικης πεπτιδασης i
PH12020551425A1 (en) Rimegepant for cgrp related disorders
AU2017265011B2 (en) Methods of administering high concentrations of nitric oxide
MX360045B (es) Combinaciones farmacéuticas de un inhibidor de cdk4/6 y un inhibidor de b-raf.
NO20072920L (no) Kombinasjon av metylxantinforbindelser og steroider for a behandle kroniske respirasjonssykdommer
PH12020500543A1 (en) Nonracemic mixtures and uses thereof
RU2017134443A (ru) Способ лечения с применением традипитанта
EA201891931A1 (ru) Новые ингибиторы фосфатидилинозитол-3-киназы гамма
PH12014502662A1 (en) Novel dosage form and formulation of abediterol
EA201590019A1 (ru) Ингаляторы сухого порошка, содержащие носитель, отличный от лактозы
EA201370230A1 (ru) Новые ингибиторы rock
PH12020500096A1 (en) Therapeutic combination of a third generation egfr tyrosine kinase inhibitor and a raf inhibitor
EA201591415A1 (ru) Фармацевтические композиции, включающие многокомпонентные кристаллические частицы, подходящие для применения в ингаляционной терапии
EA201201393A1 (ru) Ингалятор, разработанный для доставки лекарственного средства в виде сухого порошка
WO2016025671A3 (en) Treatment of sleep apnea with a combination of a carbonic anhydrase inhibitor and an aldosterone antagonist
MX2020010977A (es) Procedimientos de tratamiento de infecciones fúngicas.
UA115989C2 (uk) Фармацевтична композиція для інгалятора сухого порошку, що містить антагоністи мускаринових рецепторів тривалої дії
MX2018013475A (es) Acido carboxilico para tratar/prevenir congestion nasal.
MX2021014343A (es) Una composicion de polvo inhalable de dosis fijas que comprende glicopirronio, formoterol y propionato de fluticasona.
EA202091376A1 (ru) Нерацемические смеси и их применения
WO2018090004A3 (en) Tuberculosis therapeutic compounds and methods
UA83932U (ru) Способ лечения больных хроническим обструктивным заболеванием легких, совмещенным с неалкогольным стеатогепатитом
MX2019006548A (es) Composicion para el tratamiento de la osteoartritis.